Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: GPS2

Gene summary for GPS2

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

GPS2

Gene ID

2874

Gene nameG protein pathway suppressor 2
Gene AliasAMF-1
Cytomap17p13.1
Gene Typeprotein-coding
GO ID

GO:0000122

UniProtAcc

Q13227


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
2874GPS2LZE2THumanEsophagusESCC5.44e-107.33e-010.082
2874GPS2LZE3DHumanEsophagusHGIN8.88e-076.74e-010.0668
2874GPS2LZE4THumanEsophagusESCC6.89e-317.05e-010.0811
2874GPS2LZE5THumanEsophagusESCC8.47e-114.86e-010.0514
2874GPS2LZE7THumanEsophagusESCC7.39e-216.82e-010.0667
2874GPS2LZE8THumanEsophagusESCC1.17e-143.72e-010.067
2874GPS2LZE20THumanEsophagusESCC4.10e-174.14e-010.0662
2874GPS2LZE21D1HumanEsophagusHGIN7.28e-115.94e-010.0632
2874GPS2LZE22D1HumanEsophagusHGIN6.24e-145.73e-010.0595
2874GPS2LZE22THumanEsophagusESCC1.54e-177.33e-010.068
2874GPS2LZE24D1HumanEsophagusHGIN3.66e-039.22e-010.054
2874GPS2LZE24THumanEsophagusESCC5.67e-631.31e+000.0596
2874GPS2LZE22D3HumanEsophagusHGIN1.73e-024.36e-010.0653
2874GPS2LZE21THumanEsophagusESCC2.27e-117.55e-010.0655
2874GPS2LZE6THumanEsophagusESCC1.60e-166.46e-010.0845
2874GPS2P1T-EHumanEsophagusESCC1.05e-175.81e-010.0875
2874GPS2P2T-EHumanEsophagusESCC3.28e-142.65e-010.1177
2874GPS2P4T-EHumanEsophagusESCC1.81e-305.50e-010.1323
2874GPS2P5T-EHumanEsophagusESCC9.20e-061.52e-010.1327
2874GPS2P8T-EHumanEsophagusESCC9.67e-183.67e-010.0889
Page: 1 2 3 4 5 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0007265ColorectumADRas protein signal transduction104/3918337/187231.01e-052.35e-04104
GO:0051056ColorectumADregulation of small GTPase mediated signal transduction94/3918302/187231.81e-053.76e-0494
GO:0046578ColorectumADregulation of Ras protein signal transduction56/3918189/187232.85e-032.14e-0256
GO:00072651ColorectumMSSRas protein signal transduction91/3467337/187237.20e-051.21e-0391
GO:00510561ColorectumMSSregulation of small GTPase mediated signal transduction82/3467302/187231.31e-041.99e-0382
GO:00510562ColorectumFAPregulation of small GTPase mediated signal transduction78/2622302/187233.25e-082.85e-0678
GO:00072652ColorectumFAPRas protein signal transduction80/2622337/187239.61e-074.33e-0580
GO:00465781ColorectumFAPregulation of Ras protein signal transduction47/2622189/187234.67e-059.60e-0447
GO:00510563ColorectumCRCregulation of small GTPase mediated signal transduction69/2078302/187233.34e-099.08e-0769
GO:00072653ColorectumCRCRas protein signal transduction70/2078337/187231.49e-071.66e-0570
GO:00465782ColorectumCRCregulation of Ras protein signal transduction43/2078189/187233.26e-061.47e-0443
GO:190332027EsophagusHGINregulation of protein modification by small protein conjugation or removal78/2587242/187231.40e-132.26e-1178
GO:003139627EsophagusHGINregulation of protein ubiquitination64/2587210/187233.02e-102.71e-0864
GO:190332127EsophagusHGINnegative regulation of protein modification by small protein conjugation or removal33/258795/187232.07e-079.95e-0633
GO:003139727EsophagusHGINnegative regulation of protein ubiquitination30/258783/187232.72e-071.28e-0530
GO:000020916EsophagusHGINprotein polyubiquitination58/2587236/187236.29e-061.97e-0458
GO:003052220EsophagusHGINintracellular receptor signaling pathway62/2587265/187231.63e-054.50e-0462
GO:19029142EsophagusHGINregulation of protein polyubiquitination11/258727/187235.28e-047.56e-0311
GO:003320910EsophagusHGINtumor necrosis factor-mediated signaling pathway26/258799/187237.45e-049.90e-0326
GO:00705345EsophagusHGINprotein K63-linked ubiquitination17/258756/187231.07e-031.32e-0217
Page: 1 2 3 4 5 6 7 8 9 10 11 12 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa0516639EsophagusHGINHuman T-cell leukemia virus 1 infection51/1383222/84655.84e-034.05e-023.22e-0251
hsa05166114EsophagusHGINHuman T-cell leukemia virus 1 infection51/1383222/84655.84e-034.05e-023.22e-0251
hsa05166211EsophagusESCCHuman T-cell leukemia virus 1 infection164/4205222/84658.13e-142.09e-121.07e-12164
hsa05166310EsophagusESCCHuman T-cell leukemia virus 1 infection164/4205222/84658.13e-142.09e-121.07e-12164
hsa0516622LiverHCCHuman T-cell leukemia virus 1 infection139/4020222/84653.17e-062.79e-051.55e-05139
hsa0516632LiverHCCHuman T-cell leukemia virus 1 infection139/4020222/84653.17e-062.79e-051.55e-05139
hsa0516630Oral cavityOSCCHuman T-cell leukemia virus 1 infection150/3704222/84653.68e-137.26e-123.70e-12150
hsa05166113Oral cavityOSCCHuman T-cell leukemia virus 1 infection150/3704222/84653.68e-137.26e-123.70e-12150
hsa0516662Oral cavityNEOLPHuman T-cell leukemia virus 1 infection50/1112222/84656.91e-055.23e-043.29e-0450
hsa0516672Oral cavityNEOLPHuman T-cell leukemia virus 1 infection50/1112222/84656.91e-055.23e-043.29e-0450
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
GPS2SNVMissense_Mutationnovelc.632N>Cp.Arg211Thrp.R211TQ13227protein_codingdeleterious(0)benign(0.001)TCGA-5L-AAT1-01Breastbreast invasive carcinomaFemale<65III/IVHormone TherapyletrozolSD
GPS2insertionFrame_Shift_Insnovelc.161_162insAp.Glu55GlyfsTer42p.E55Gfs*42Q13227protein_codingTCGA-A2-A04V-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapycytoxanPD
GPS2insertionNonsense_Mutationnovelc.181_182insAATp.Met60_Ser61insTerp.M60_S61ins*Q13227protein_codingTCGA-A2-A0EO-01Breastbreast invasive carcinomaFemale<65I/IIHormone TherapytamoxiphenSD
GPS2deletionFrame_Shift_Delc.310delGp.Glu104AsnfsTer5p.E104Nfs*5Q13227protein_codingTCGA-A2-A0SY-01Breastbreast invasive carcinomaFemale<65III/IVHormone TherapyarimidexSD
GPS2deletionFrame_Shift_Delnovelc.517_536delNNNNNNNNNNNNNNNNNNNNp.Gly173IlefsTer26p.G173Ifs*26Q13227protein_codingTCGA-A8-A07R-01Breastbreast invasive carcinomaFemale>=65III/IVAncillaryzoledronicSD
GPS2deletionFrame_Shift_Delc.141_148delACAGGAGAp.Gln48LysfsTer46p.Q48Kfs*46Q13227protein_codingTCGA-AR-A24O-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapycytoxanPD
GPS2deletionFrame_Shift_Delnovelc.469delNp.Gln157LysfsTer188p.Q157Kfs*188Q13227protein_codingTCGA-E2-A15I-01Breastbreast invasive carcinomaFemale<65I/IIHormone TherapytamoxiphenSD
GPS2deletionFrame_Shift_Delc.281delTp.Leu94TyrfsTer15p.L94Yfs*15Q13227protein_codingTCGA-EW-A1PG-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapydocetaxelSD
GPS2SNVMissense_Mutationnovelc.709C>Gp.Gln237Glup.Q237EQ13227protein_codingtolerated_low_confidence(0.26)benign(0.015)TCGA-JW-A5VL-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
GPS2SNVMissense_Mutationrs780901898c.902N>Tp.Ser301Leup.S301LQ13227protein_codingdeleterious_low_confidence(0)possibly_damaging(0.776)TCGA-MY-A5BE-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
Page: 1 2 3 4 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1